Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SCYNEXISSCYX -4.57%34 3-Year EPS without NRI Growth Rate is 47.60% as of Jun. 2026, which is 28% above its 10-year median of 37.15. GuruFocus rates SCYX with a GF Score™ of 34/100 and a GF Value™ of $17.63 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 786 Drug Manufacturers companies, SCYNEXIS ranks better than 87.02% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 47.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of SCYNEXIS was 53.70% per year. The lowest was 15.70% per year. And the median was 37.15% per year.
SCYNEXIS (NAS:SCYX) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
SCYNEXIS 3-Year EPS without NRI Growth Rate Related Terms
SCYX vs TLPH, IXHL, CPHI: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SCYNEXIS 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where SCYNEXIS's 3-Year EPS without NRI Growth Rate falls into.
SCYNEXIS 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 47.60% mean?
SCYNEXIS (SCYX) has a 3-Year EPS without NRI Growth Rate of 47.60% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for SCYNEXIS and its competitors. This is 28% above median its historical median of 37.15. Over the past decade, SCYNEXIS's 3-Year EPS without NRI Growth Rate has ranged from 15.70 to 53.70. According to the industry distribution chart, SCYNEXIS ranks #102 out of 786 companies in the Drug Manufacturers industry, placing it in the top 13%.
Is SCYNEXIS's 3-Year EPS without NRI Growth Rate too high?
SCYNEXIS's current 3-Year EPS without NRI Growth Rate of 47.60% is 28% above median its 10-year median of 37.15. Over the past 10 years, this metric has ranged from a low of 15.70 to a high of 53.70. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.65. SCYNEXIS's value of 47.60% is 393.3% above this industry median. Based on the distribution chart, SCYNEXIS ranks #102 out of 786 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, SCYNEXIS has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SCYNEXIS's 3-Year EPS without NRI Growth Rate compare to TLPH and IXHL?
According to the Drug Manufacturers industry distribution chart, SCYNEXIS ranks #102 out of 786 companies for 3-Year EPS without NRI Growth Rate. This places SCYNEXIS in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 9.65. SCYNEXIS's value of 47.60% is 393.3% above this benchmark. Historically, SCYNEXIS's own 3-Year EPS without NRI Growth Rate has ranged from 15.70 to 53.70 over the past decade. While the company's 10-year median is 37.15 vs. the industry median of 9.65, SCYNEXIS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.65, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SCYNEXIS's current 3-Year EPS without NRI Growth Rate of 47.60% is 393.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for SCYNEXIS and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SCYNEXIS's current 3-Year EPS without NRI Growth Rate is 47.60%, which is 28% above median its own 10-year median of 37.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SCYNEXIS stock overvalued right now?
Based on GuruFocus' analysis, SCYNEXIS (SCYX) is currently considered Possible Value Trap. The stock's GF Value™ is $17.63, compared to a current price of $4.38 — trading 75.2% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 47.60%, which is 28% above median its 10-year median of 37.15 and 393.3% above the Drug Manufacturers industry median of 9.65. SCYNEXIS's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For SCYNEXIS (SCYX), the current 3-Year EPS without NRI Growth Rate is 47.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SCYNEXIS (SCYX) Overvalued in 2026?
Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued.
The current stock price of $4.38 is trading 75.2% below its estimated GF Value™ of $17.63.
GuruFocus considers SCYNEXIS to be Possible Value Trap.
Key valuation signals for SCYX:
3-Year EPS without NRI Growth Rate: 47.60% (28% above median its 10-year median of 37.15)
GF Value™: $17.63 vs. price of $4.38 (75.2% below fair value)
Industry Position: 393.3% above the Drug Manufacturers median (#102 of 786)
No single metric tells the full story. See the SCYX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
34GF Score
Get the complete analysis for SCYX
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCYX has been successfully added to your 
